Literature DB >> 19522885

A recipient of immunoglobulin from a donor who developed vCJD.

T El-Shanawany, S Jolles, D J Unsworth, P Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19522885     DOI： 10.1111/j.1423-0410.2008.01148.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN： 0042-9007            Impact factor:   2.144


× No keyword cloud information.
  3 in total

1.  Pathogen reduction of blood bank components: a matter of swings and roundabouts.

Authors:  Albert Farrugia; Vincenzo De Angelis
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

Review 2.  Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.

Authors:  Albert Farrugia; Giancarlo M Liumbruno; Fabio Candura; Samantha Profili; Josephine Cassar
Journal:  Blood Transfus       Date:  2018-09-03       Impact factor: 3.443

Review 3.  Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacy.

Authors:  Albert Farrugia; Isabella Quinti
Journal:  Front Immunol       Date:  2014-12-23       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.